Evidence map›Paper›PMID 41933220›Full record

ArticleJournal of cancer research and clinical oncology2026

Improving the diagnosis of renal tumours of young people through integrated molecular analysis.

Sarah M Leiter, Aisosa O Guobadia, Ben Fleming, Thankamma V Ajithkumar, James N Armitage, G A Amos Burke, Charlotte M Burns, Nicholas Coleman, Helen Hatcher, Gail Horan and 17 more

Abstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Sarah M Leiter *Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Aisosa O Guobadia *Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Ben FlemingDepartment of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Thankamma V AjithkumarDepartment of Clinical Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
James N ArmitageDepartment of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
G A Amos BurkeCancer Research UK Clinical Trials Unit, School of Medical Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Charlotte M BurnsDepartment of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Nicholas ColemanDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Helen HatcherDepartment of Oncology, Cambridge University Hospital NHS Trust, Cambridge, CB2 0QQ, UK.
Gail HoranDepartment of Clinical Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Anna-May LongDepartment of Paediatric Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Sarah McDonaldDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Thomas J MitchellDepartment of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
James C NicholsonDepartment of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Thomas RobertsEast Genomics Laboratory Hub (E-GLH) Genetics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Grant D StewartDepartment of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
John A TadrossDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Patrick S TarpeyEast Genomics Laboratory Hub (E-GLH) Genetics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Claire TrayersDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Jamie TrotmanEast Genomics Laboratory Hub (E-GLH) Genetics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
James A WatkinsDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Anne Y WarrenDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Gordan M VujanicDepartment of Pathology, Sidra Medicine, Doha, Qatar.
Ruth ArmstrongDepartment of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Sam BehjatiDepartment of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK. sb31@sanger.ac.uk.
C Elizabeth HookDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK. lizhook@nhs.net.
Matthew J MurrayDepartment of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK. mjm16@cam.ac.uk.

Funding

Cancer Research UK Cambridge Institute, University of Cambridge C9685/A25177Mark Foundation For Cancer Research RG95043National Institute for Health and Care Research ACF-2022-14-009NIHR Cambridge Biomedical Research Centre NIHR203312University of Cambridge Kidney Care FundWellcome Trust 220540/Z/20/A
6 · The paper itself

Abstract

backgroundRenal tumours account for one in twenty paediatric cancers, with Wilms tumour (WT) the most common in young children and renal cell carcinoma (RCC) predominating in adolescents and young adults. Diagnostic work-up has traditionally focused on clinical features, radiology, and histology, with a limited role for molecular analysis. However, it is estimated that up to one-third of children with WT have underlying cancer predisposition, which could necessitate prolonged treatment and intensive follow-up.

methodsHere we describe five children and young adults treated at a single regional centre in England who had paired tumour and germline whole genome sequencing (WGS) as part of their routine diagnostic work-up.

resultsOne child diagnosed radiologically with a WT underwent pre-operative chemotherapy with good clinical and imaging response. Histological examination of the resection raised concerns over RCC; however, WGS was able to confirm that this was a WT with pathognomonic somatic WT changes. A young adult with upfront nephrectomy had a difficult-to-classify tumour; WGS revealed a novel ERC1-CCNY fusion as a likely novel driver event. Two further children, who did not meet clinical criteria for cancer predisposition testing, had predisposition syndromes identified via agnostic WGS. Finally, a child with piebaldism had a WT-associated REST deletion identified early through critical clinical thinking and expedited microarray.

conclusionWe highlight that molecular analysis, particularly agnostic WGS, has a key routine role in the care of children with renal tumours. It is likely that outcomes for these young people have been improved through more accurate diagnosis and early detection of cancer predisposition.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsWilms TumorAdolescentChildChild, PreschoolFemaleGenetic Predisposition to DiseaseHumansMaleWhole Genome SequencingYoung AdultCancer predispositionMolecular analysisRenal cell carcinomaWhole genome sequencingWilms tumour

Identifiers

PMID41933220
PMCPMC13049143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.